NASDAQ:PDSB PDS Biotechnology (PDSB) Stock Price, News & Analysis $3.88 -0.06 (-1.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.85▼$4.0750-Day Range$2.55▼$4.2352-Week Range$2.53▼$6.85Volume142,020 shsAverage Volume757,121 shsMarket Capitalization$142.32 millionP/E RatioN/ADividend YieldN/APrice Target$16.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get PDS Biotechnology alerts: Email Address PDS Biotechnology MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside329.6% Upside$16.67 Price TargetShort InterestHealthy15.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.46) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.41 out of 5 starsMedical Sector742nd out of 936 stocksPharmaceutical Preparations Industry345th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingPDS Biotechnology has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePDS Biotechnology has only been the subject of 3 research reports in the past 90 days.Read more about PDS Biotechnology's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted15.54% of the outstanding shares of PDS Biotechnology have been sold short.Short Interest Ratio / Days to CoverPDS Biotechnology has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in PDS Biotechnology has recently decreased by 18.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPDS Biotechnology does not currently pay a dividend.Dividend GrowthPDS Biotechnology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PDSB. Previous Next 2.5 News and Social Media Coverage News SentimentPDS Biotechnology has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.Search Interest7 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PDS Biotechnology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of PDS Biotechnology is held by insiders.Percentage Held by InstitutionsOnly 26.84% of the stock of PDS Biotechnology is held by institutions.Read more about PDS Biotechnology's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for PDS Biotechnology are expected to decrease in the coming year, from ($1.46) to ($1.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PDS Biotechnology is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PDS Biotechnology is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPDS Biotechnology has a P/B Ratio of 4.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PDS Biotechnology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsJ.P. Morgan’s DIRE WarningWhen the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."Click here to see why Wall Street is in PANIC mode >>> About PDS Biotechnology Stock (NASDAQ:PDSB)PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Read More PDSB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PDSB Stock News HeadlinesJuly 23 at 3:53 AM | americanbankingnews.comPDS Biotechnology (NASDAQ:PDSB) Stock Price Up 0.8%July 22, 2024 | msn.comReopen PDS shops, says DMK, warns of protest in PuducherryJuly 26, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.May 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for PDS Biotechnology on Strong Financials and Promising Clinical PipelineMay 15, 2024 | investorplace.comPDSB Stock Earnings: PDS Biotechnology Beats EPS for Q1 2024May 15, 2024 | sfgate.comPDS Biotechnology: Q1 Earnings SnapshotMay 15, 2024 | msn.comPDS Biotechnology GAAP EPS of -$0.30 beats by $0.06May 15, 2024 | globenewswire.comPDS Biotech Provides Business Update and Reports First Quarter 2024 Financial ResultsJuly 26, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for PDS Biotechnology on Promising Clinical Data and Strategic FocusMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on PDS Biotechnology’s Promising HNSCC Treatment DevelopmentsMay 9, 2024 | globenewswire.comPDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck CancerMay 9, 2024 | finance.yahoo.comPDS Biotech to Participate in Upcoming May 2024 Investor ConferencesMay 7, 2024 | finance.yahoo.comPDS Biotech to Announce First Quarter 2024 Financial Results on May 15, 2024May 3, 2024 | globenewswire.comPDS Biotechnology Announces Details of Virtual KOL EventMay 2, 2024 | globenewswire.comPDS Biotech Appoints Stephan Toutain as Chief Operating OfficerApril 29, 2024 | seekingalpha.comPDS Biotechnology: Entering A Holding Pattern While Cash Remains A Concern (Rating Downgrade)April 23, 2024 | globenewswire.comPDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck CancerSee More Headlines Receive PDSB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PDS Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PDSB CUSIPN/A CIK1472091 Webwww.pdsbiotech.com Phone(800) 208-3343Fax908-790-1212Employees25Year FoundedN/APrice Target and Rating Average Stock Price Target$16.67 High Stock Price Target$21.00 Low Stock Price Target$9.00 Potential Upside/Downside+330.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-145.99% Return on Assets-70.40% Debt Debt-to-Equity Ratio0.45 Current Ratio4.56 Quick Ratio4.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.84 per share Price / Book4.61Miscellaneous Outstanding Shares36,680,000Free Float33,011,000Market Cap$141.95 million OptionableOptionable Beta1.91 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Frank K. Bedu-Addo Ph.D. (Age 59)President, CEO & Director Comp: $853.85kDr. Gregory L. Conn Ph.D. (Age 69)Chief Scientific Officer Comp: $194.67kMr. Lars Robert Boesgaard M.B.A. (Age 54)Principal Financial & Accounting Officer and CFO Mr. Stephan Toutain M.B.A. (Age 58)M.S., Chief Operating Officer Dr. Joe J. DervanVP of Research & DevelopmentMs. Deanne RandolphHead of Investor RelationsMr. Spencer Brown J.D. (Age 54)Senior VP, General Counsel, Corporate Secretary & Compliance Officer Dr. Kirk V. Shepard M.D. (Age 72)Chief Medical Officer Ms. Janetta Trochimiuk (Age 61)Controller More ExecutivesKey CompetitorsSelecta BiosciencesNASDAQ:SELBInovio PharmaceuticalsNASDAQ:INOCorbus PharmaceuticalsNASDAQ:CRBPSavaraNASDAQ:SVRAApplied TherapeuticsNASDAQ:APLTView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpSold 69,555 shares on 7/26/2024Ownership: 0.080%Tempus Wealth Planning LLCBought 18,800 shares on 7/25/2024Ownership: 0.051%Inspirion Wealth Advisors LLCBought 4,917 shares on 7/13/2024Ownership: 0.981%Vanguard Group Inc.Bought 82,135 shares on 5/10/2024Ownership: 4.329%View All Institutional Transactions PDSB Stock Analysis - Frequently Asked Questions How have PDSB shares performed this year? PDS Biotechnology's stock was trading at $4.97 at the beginning of the year. Since then, PDSB shares have decreased by 21.9% and is now trading at $3.88. View the best growth stocks for 2024 here. How were PDS Biotechnology's earnings last quarter? PDS Biotechnology Co. (NASDAQ:PDSB) released its quarterly earnings data on Wednesday, May, 15th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. Who are PDS Biotechnology's major shareholders? PDS Biotechnology's top institutional investors include Inspirion Wealth Advisors LLC (0.98%), Bank of New York Mellon Corp (0.08%) and Tempus Wealth Planning LLC (0.05%). View institutional ownership trends. How do I buy shares of PDS Biotechnology? Shares of PDSB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of PDS Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that PDS Biotechnology investors own include Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Boxlight (BOXL), Otonomy (OTIC), Bionano Genomics (BNGO) and CymaBay Therapeutics (CBAY). This page (NASDAQ:PDSB) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PDS Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share PDS Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.